Inflammation in Nonalcoholic Steatohepatitis

R Christopher Harmon; Dina G Tiniakos; Curtis K Argo


Expert Rev Gastroenterol Hepatol. 2011;5(2):189-200. 

In This Article

Five-year View

Over the next 5 years, the results of large, well-designed, prospective studies will hopefully establish the general applicability of noninvasive tests for predicting necroinflammation and assessing advanced fibrosis in NAFLD. While reduction of hepatic steatosis may not be the most desirable ultimate goal based on current evidence indicating its hepatoprotective role against the lipotoxic effects of FFAs and their metabolites, we expect that clinical therapeutic trials of new agents targeting pathways instrumental in the initiation and evolution of hepatic and/or visceral adipose tissue inflammation and associated downstream mediators will demonstrate promising results.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.